23andMe shares slide more than 15% as lower services revenue hits Q3 results
By James Rogers
23andMe also lowered its full year revenue outlook
Shares of 23andMe Holding Co. fell 15.8% Thursday after the DNA-testing company fiscal third-quarter sales declined 33%, weighed down by lower consumer services and research revenue.
The stock's performance puts 23andMe (ME) shares on pace for their biggest daily percentage decline since Nov. 9, 2023, they fell 21.96%, according to Dow Jones Market Data. The stock is also on pace for its fourth-worst daily percentage decline.
23andMe's third-quarter revenue was $44.7 million, down from $66.9 million in the prior year's quarter. The company said this was due to lower research revenue after the conclusion of its exclusive GSK PLC AR (GSK) collaboration in July 2023 and lower consumer services revenue driven mainly by lower PGS (Preimplantation Genetic Screening) kit sales volume and telehealth orders. These decreases were partially offset by higher revenue from non-recurring payments from other research partners as well as growth in 23andMe's membership services revenue, the company said. Analysts surveyed by FactSet were looking for sales of $54 million.
Related: 23andMe to offer clients personalized action plans based on genetic and other health data
Revenue from consumer services, which includes PGS, telehealth and membership services, accounted for approximately 96% of 23andMe's total third-quarter revenue, the company said. Research services revenue accounted for approximately 4% of 23andMe's total revenue.
The company reported a net loss of $278 million, or a loss of 58 cents a share, compared to a net loss of $92 million, or a loss of 20 cents a share, in the year-ago quarter. Analysts surveyed by FactSet were expecting a loss of 14 cents a share.
23andMe also lowered its full-year revenue guidance to between $215 million and $220 million, from its prior forecast of $240 million to $250 million.
Related: 23andMe confirms hackers accessed ancestry data of 6.9 million people
Shares of 23andMe have fallen 77.6% in the last 52 weeks, compared with the S&P 500 index's SPX gain of 22.3%.
-James Rogers
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
02-08-24 1030ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
What I Hope My 14-Year-Old Learned at Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Amazon Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Dividend Stocks
-
3 Stocks With High Dividend Yields That Warren Buffett Likes
-
How to Invest Like Warren Buffett
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?